AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00915070 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline solution
Description: infusion period 60 minutes
Study NCT00915070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
Study NCT00915070 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser Doppler Flowmetry
Description: blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
Study NCT00996723 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vandetanib and dasatinib
Description: Two oral investigational agents (vandetanib \[VEGFR2, RET, and EGFR inhibitor\] and dasatinib \[bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor\] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
Study NCT03309046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REACH Individual Session
Description: Individual telephone session with parent
Study NCT03309046 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Webinar
Description: Videos with information on caregiving
Study NCT02354482 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Communication and Care Management
Description: Received the following Transitional Care strategies:~1. Helpful Health Care Contact OR Symptom Management~2. Post-discharge Care Consultation~3. Patient Goal/Preference Assessment~4. Plain Language Communication in Hospital~5. Plain Language Communication at Home~6. Transition Summary for Patients and Family Caregivers
Study NCT02354482 — intervention group
Intervention type: BEHAVIORAL
Intervention: Home-Based Trust, Plain Language, and Coordination
Description: Received the following Transitional Care Strategies:~1. Transition Team~2. Home visits~3. Plain Language Communication at Home~4. Promote Trust at Home~5. Referral to Community Services~6. Follow-up Appointment
Study NCT02354482 — intervention group
Intervention type: BEHAVIORAL
Intervention: Hospital-Based Trust, Plain Language, and Coordination
Description: Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Identify High-Risk Patients and Intervene~3. Medication Reconciliation~4. Plain Language Communication in Hospital~5. Promote Trust in the Hospital~6. Transition Summary for Patients and Family Caregivers
Study NCT02354482 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient/Caregiver Assessment and Provider Information Exchange
Description: Received the following Transitional Care Strategies:~1. Patient Goal/Preference Assessment~2. Identify High-Risk Patients and Intervene~3. Timely Exchange of Critical Patient Information among Providers~4. Patient/Family Caregiver Transitional Care Needs Assessment
Study NCT02354482 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessment and Teach Back
Description: Received the following Transitional Care Strategies:~1. Post-discharge care consultation~2. Language Assessment~3. Teach Back for Information and Skills
Study NCT02354482 — intervention group
Intervention type: OTHER
Intervention: Standard of Care (Reference)
Description: No specific Transitional Care Strategy
Study NCT03839927 — intervention group
Intervention type: OTHER
Intervention: Validity and reliability of Life-Space Assesment
Description: Life-Space Assesment and SF-36 surveys will be applied. The reliability and validity of the results will be analyzed.
Study NCT01353833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aldesleukin
Description: 0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
Study NCT00328198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.~Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study.
Study NCT03783702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OxyCODONE 5 Mg (milligram) Oral Tablet
Description: Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
Study NCT03783702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OxyCODONE 5 Mg (milligram) Oral Tablet
Description: Oxycodone will be the second-line treatment in the control group and the third-line treatment in the experimental group.
Study NCT00915070 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Goldmann Applanation Tonometer
Description: intraocular pressure measurements
Study NCT00915070 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Goldmann Applanation Tonometer
Description: intraocular pressure measurements
Study NCT00915070 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: squatting
Description: subjects will perform squatting for 6 minutes while blood flow measurements
Study NCT00915070 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: squatting
Description: subjects will perform squatting for 6 minutes while blood flow measurements
Study NCT00136903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal® - 2 Million cells/kg
Description: 2 million hMSCs/kg actual body weight, IV on study Days 1 and 4
Study NCT00136903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prochymal®- 8 Million cells/kg
Description: 8 million hMSCs/kg actual body weight IV on study Days 1 and 4
Study NCT00136903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone 2 mg/kg administered intravenously.
Study NCT00136903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 2.5 mg/kg administered orally.
Study NCT00136903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Administered as prescribed by the caregiver.
Study NCT00136903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Administered as prescribed by the caregiver.
Study NCT00136903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Administered as prescribed by the caregiver.
Study NCT00328198 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.~Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration.
Study NCT02290639 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Treatment
Description: Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
Study NCT02290639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Cognitive Behavioral Treatment
Description: Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
Study NCT02290639 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Contact
Description: Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
Study NCT04149327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin 500 mg + metronidazole 500 mg
Description: 500 mg amoxicillin and 500 mg metronidazole to be taken every 8 hours for 7 days
Study NCT04149327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-surgical periodontal and peri-implant treatment
Description: Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned.
Study NCT02011308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Green light Laser
Description: Laser vs TURP
Study NCT00263458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
Description: Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
Study NCT00263458 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting
Description: Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
Study NCT02197416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
Study NCT02011308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the Prostate (TURP)
Description: Laser vs TURP
Study NCT01627847 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Study NCT01627847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Study NCT02165124 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Embolization Device
Description: Embosphere Microspheres
Study NCT01594658 — intervention group
Intervention type: PROCEDURE
Intervention: Foam sclerotherapy
Description: Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
Study NCT01594658 — intervention group
Intervention type: PROCEDURE
Intervention: conservative
Description: This arm only has medical standard handling (healings performed by the nurse group)
Study NCT02019433 — intervention group
Intervention type: DEVICE
Intervention: Structan®
Study NCT01813422 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT01813422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT04288466 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin solution 450ml
Study NCT02781064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months
Study NCT02781064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin 20mg
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months
Study NCT02781064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months
Study NCT02781064 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Atorvastatin and matching placebo to be taken in a randomised order for 12 months
Study NCT01515319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y242
Description: Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 90 mg Y242 (Part A); Multiple ascending dose: Y242 single subcutaneous dose, administered once a week for 5 weeks (Part B)
Study NCT01515319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline
Description: Identical volume to that of Y242
Study NCT00527085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 073
Description: 30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Study NCT00527085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
Study NCT02773251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid-carboxymethylcellulose
Study NCT00747929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-2367 Placebo
Description: four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks,
Study NCT00747929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 800 mg
Description: two 400 mg S-2367 tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for a total of 54 weeks
Study NCT00747929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-2367 1600 mg
Description: four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet for total of 54 weeks,
Study NCT00990574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wiley Spinal Catheter
Description: The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
Study NCT00990574 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia Group (SAG)
Description: The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position.
Study NCT04149327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-surgical periodontal and peri-implant treatment
Description: Patients are instructed on how to perform proper oral hygiene measures using an electric toothbrush, interdental brushes (to be used in combination with Corsodyl® gel) and floss (Oral-B® superfloss or Meridol® floss, at implants only).~Patients will receive full-mouth mechanical cleansing of both implants and remaining dentition using ultrasonic instruments (EMS®) and hand instruments (scalers and curettes) in one or multiple sessions (max. 4). Prior to each session patients will rinse their mouth using 0.12% chlorhexidine + 0.05% cetylpyridinium chloride without alcohol during 30 seconds. At the final session all previously cleaned areas will be re-examined and cleaned.
Study NCT01646008 — intervention group
Intervention type: OTHER
Intervention: To measure carbon dioxide by capnography and arterial blood
Description: Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
Study NCT01646008 — intervention group
Intervention type: OTHER
Intervention: to measure carbon dioxide by capnography and arterial blood
Description: three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
Study NCT03896568 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oncolytic Adenovirus Ad5-DNX-2401
Description: Given IA
Study NCT03896568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT00747929 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduced Calorie Diet
Description: A diet with restricted calorie content
Study NCT00747929 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reduced Calorie Diet
Description: A diet with restricted calorie content
Study NCT02548195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin and gemcitabine
Description: oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
Study NCT02548195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
Study NCT00083174 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: exemestane
Description: one 25 mg tablet daily in am
Study NCT03092544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dimethyl fumarate
Description: Active drug
Study NCT02554513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EPG Tx
Description: behavioral intervention that incorporates a device that provides visual biofeedback
Study NCT02554513 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPT
Description: A treatment hierarchy involving integral stimulation
Study NCT02402764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m\^2).
Study NCT03704298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert
Study NCT03704298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert
Study NCT04266548 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superselective Intra-arterial Hepatic Injection of Indocyanine Green (ICG) for Fluorescence Image-guided Segmental Positive Staining
Description: The patients with single HCC which is planned to received laparoscopic hepatectomy were involved. Procedures were performed in conventional angiography room. The celiac trunk was catheterized and a microcatheter was advanced into segmental hepatic artery branches which supplied the HCC. The 5cc 0.125 mg/cc ICG was injected from super-selective hepatic artery in operative room. A Near-Infrared laparoscope was used to detect the fluorescent signal to assess the correspondence between arterial-based fluorescence demarcation and ultrasound-based surgical demarcation.
Study NCT00804973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2590443
Description: 200 milligrams (mg) as four 50-mg capsules, oral, once
Study NCT00804973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: saline solution, injection, once
Study NCT03704298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously
Study NCT00804973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: saline solution, injection, once
Study NCT03704298 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Utomilumab
Description: Administered as an IV infusion